Organon reports positive phase 3 results on Roche Perjuta biosimilar [Seeking Alpha]
Organon & Co. (OGN)
Company Research
Source: Seeking Alpha
That endpoint was the total pathological complete response (tpCR). Secondary endpoints still under evaluation include tpCR rate assessed by investigators; breast pathologic complete response rate; objective response rate; event-free survival; disease-free survival; safety; pharmacokinetics; and immunogenicity. Organon has global commercialization rights for the biosimilar, HLX11, except for China, where Shanghai Henlius has rights. Perjuta is approved for the treatment of HER2-positive breast cancer. More on Organon Organon: A Surprising Deal Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis Organon & Co.: Cheap With Caveats Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma Eli Lilly, Organon expand distribution deal for migraine drug Recommended For You Comments More Trending News Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
OGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGN alerts
High impacting Organon & Co. news events
Weekly update
A roundup of the hottest topics
OGN
News
- Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade) [Seeking Alpha]Seeking Alpha
- Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and OlderBusiness Wire
- Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know [Yahoo! Finance]Yahoo! Finance
- Organon Reports Results for the Third Quarter Ended September 30, 2024Business Wire
- US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)Business Wire
OGN
Earnings
- 10/31/24 - Beat
OGN
Sec Filings
- 11/8/24 - Form 4
- 11/5/24 - Form 8-K
- 11/1/24 - Form 10-Q
- OGN's page on the SEC website